公开(公告)号：US20170096417A1

公开(公告)日：2017-04-06

申请号：US15023269

申请日：2014-09-19

Applicant: KARYOPHARM THERAPEUTICS INC.

Inventor： Erkan Baloglu ,  Sharon Shacham ,  William Senapedis ,  Dilara McCauley ,  Yosef Landesman ,  Gali Golan ,  Ori Kalid ,  Sharon Schechter

IPC: C07D409/12 ,  C07D413/12 ,  C07D213/81 ,  C07D409/14 ,  C07D213/73 ,  C07D401/12

CPC classification number: C07D409/12 ,  C07D213/73 ,  C07D213/81 ,  C07D401/12 ,  C07D401/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D419/12

Abstract: The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).

公开(公告)号：US20240279188A1

公开(公告)日：2024-08-22

申请号：US18244659

申请日：2023-09-11

Applicant: Karyopharm Therapeutics Inc.

Inventor： Vincent P. Sandanayaka ,  Sharon Shacham ,  Dilara McCauley ,  Sharon Schechter

IPC: C07D249/08 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D241/20 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

CPC classification number: C07D249/08 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D241/20 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

Abstract: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I.




or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.